Investigation and treatment of imported malaria in

non-endemic countries by Whitty, CJ et al.
Investigation and treatment of imported malaria in
non-endemic countries
Christopher J MWhitty consultant physician and professor of international health121, Peter L Chiodini
consultant parasitologist 1 director and honorary professor 2, David G Lalloo professor of tropical
medicine 3
1Hospital for Tropical Diseases, London WC1E 6JB, UK ; 2PHE Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine,
London, UK; 3Liverpool School of Tropical Medicine, Liverpool, UK
Every year, several thousand people with malaria arrive in
non-endemic countries, and about 1600 arrive in the United
Kingdom alone. Case fatality in the UK, as elsewhere, is around
1% overall but varies by age and previous exposure to malaria.1-3
This rate is similar to that seen in endemic countries, but the
age profile of deaths is very different. In Africa mortality is
highest in young children, but in imported cases it is highest in
older patients, especially those over 65 years.4-6 If malaria is
treated early, with widely available drugs before it becomes
severe, death is avoidable and a full recovery almost guaranteed.
Late presentation carries a higher risk of death. Themanagement
of severe malaria is a medical emergency. This review describes
how to recognise and diagnose malaria, the current treatment
of uncomplicated malaria, and the management of patients with
severe disease. It concentrates on adults and recent advances
relevant to non-endemic high resource countries such as Europe
and North America. Different challenges arise in low resource
endemic settings and are not covered in this review.
What is malaria?
Malaria is a tropical parasitic disease of red blood cells
transmitted by anopheles mosquitoes. Five species affect
humans. The most serious, and in Europe the most common,
imported form is Plasmodium falciparummalaria, which causes
most deaths from importedmalaria. The other common imported
form is P vivaxmalaria. It is generally less severe but can recur
several months after treatment owing to relapse from
hypnozoites (“sleeping” parasites) in the liver. P ovale malaria
is similar to P vivaxmalaria, as is P malariaemalaria although
it does not relapse. P knowlesi is a monkey malaria parasite that
has recently been recognised to infect humans and is rare in
imported cases.
Who is at risk of acquiring and dying from
malaria?
Several countries that are frequented by tourists and people
visiting friends and relatives have regions where the average
person gets clinical malaria four or more times a year. One
observational study found that around one in five travellers with
a history of fever returning from sub-Saharan Africa had
malaria.7 Rates are much lower (maybe 1/100) in unwell
travellers returning from malaria endemic Asia and Latin
America, although the risk of malaria varies widely in these
continents.6 Failure to take effective prophylaxis is associated
with acquiring malaria in several observational studies.
Travellers whose families emigrated from malaria endemic
countries, and who are visiting friends and relatives, are at
particularly high risk of acquiring malaria, especially those of
west African heritage.2 People who travelled to visit friends and
relatives account for around 65% of all malaria cases in the UK,
and their reported chemoprophylaxis use is lower than for other
travellers. Vivax malaria, the form of malaria most commonly
imported fromAsia and Latin America, had been declining over
the past two decades in the UK.8
Observational studies of imported febrile illnesses in travellers
have shown that malaria remains one of the most common
potentially life threatening causes of fever in travellers.9 Such
studies also show that increasing age, delay to diagnosis,6 and
presenting in an area where malaria is seldom seen or treated
increase the risk of dying from falciparummalaria once acquired
(evidence from the UK only).6 Although in Africa most deaths
are in children, in non-endemic high resource settings
observational studies show that older people have the greatest
risk of dying from malaria if acquired, with minimal risk in
children and young adults and a steadily increasing risk over
the age range; case fatality in those over 65 years is 4.6% in the
UK.5 6
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Malaria is a common cause of fever in people returning from the tropics
Falciparum malaria is potentially fatal unless treated early, and patients over 65 years are at particular risk
In most cases, vivax malaria can be treated with chloroquine in the outpatient setting
Resistance to antimalarial drugs used to treat falciparum malaria is widespread
Artesunate is the drug of choice for severe malaria, but if this is not available do not delay treatment with quinine
Sources and selection criteria
We searched the Cochrane Library and PubMed for recent relevant trials and observational studies on imported malaria. The search was
supplemented where relevant by data from the UK Malaria Reference Laboratory and expert opinion from the PHE Advisory Committee on
Malaria Prevention in UK Travellers (ACMP) and World Health Organization expert guidelines. Good epidemiological data are available on
imported malaria in Europe and North America and on diagnostic tests. There are high quality trials of malaria treatment in endemic countries
but few large well conducted trials of treatment in travellers, so data on treatment have to be extrapolated from endemic settings.
How to recognise malaria in adults
The symptoms and signs of malaria are non-specific and overlap
with many other common infections. Influenza is a common
misdiagnosis, and case reports show that malaria has also been
misdiagnosed as gastroenteritis, hepatitis, and lower respiratory
tract infection.10 The key to diagnosing malaria is to take a travel
history for all patients and request a malaria test in anyone who
feels unwell and has recently been to an endemic country. A
history of fever will be present in most patients with malaria,
but around half will have no fever at the time of presentation;
absence of fever cannot exclude disease.7 Headache, malaise,
and rigors are common symptoms but not invariable. Certain
symptoms and signs of severe or potentially complicated
malaria—such as jaundice, seizures, or rapid breathing—can
result in the misdiagnosis of malaria—for example, as hepatitis
(table 1⇓). It is therefore essential to exclude malaria with a
thick and thin blood film rather than rely on clinical diagnosis
based on symptoms; attempts to produce algorithms that reliably
predict malaria on the basis of symptoms have been
unsuccessful.11 In patients returning from malaria endemic
countries, any symptom or sign compatible with an infection
should raise the possibility of malaria. Although most cases of
falciparum malaria present within three months of return, case
reports and Public Health England data show that some cases
in travellers present up to a year after return, and many cases
of non-falciparum malaria occur over a year later.12
How is malaria diagnosed?
The gold standard for malaria diagnosis in clinical practice
remains microscopic examination of a blood film. Good rapid
diagnostic tests for falciparum malaria with sensitivity and
specificity above 97%, and fairly good ones for non-falciparum
malaria,13 are nowwidely available to hospitals in Europe.Most,
however, are not as sensitive as an experienced microscopist
and give no information about parasite density, which is
important for prognosis and treatment decisions. Therefore these
rapid tests should be seen as an adjunct to, rather than an
alternative to, conventional microscopic diagnosis, and their
sole use is not recommended. Newer polymerase chain reaction
based diagnostic methods are currently used only in research
settings, although they will probably become clinically useful
in non-endemic settings within the next decade, especially to
detect mixed infections and potentially drug resistant cases.14
What are the indicators of severe or
complicated disease in adults?
Once malaria is diagnosed, the priority is to determine the
severity of disease because this determines treatment. Table 1
showsmodifiedWorld Health Organization indicators of severe
disease; patients with any one of these will need parenteral
treatment with antimalarial drugs. HIV positive patients have
an increased risk of severe malaria and of drug interactions.15
Observational studies have shown that three severe syndromes
predominate in adults: cerebral malaria—in practice, malaria
with reduced level of consciousness, neurological signs, or
seizures; renal failure; and acute lung injury (or acute respiratory
distress syndrome).16 Disseminated intravascular coagulation
and shock are less common and seldom occur in isolation. In
addition, jaundice (due to recent major haemolysis) or a parasite
count in the blood of greater than 2%, even if the patient does
not appear clinically unwell, is a sign that severe malaria is more
likely to develop.
What are the indicators of severe or
complicated disease in children?
Multicentre observational studies, mainly from Africa, have
shown that anaemia, raised respiratory rate due to acidosis
(rather than lung injury), and cerebral malaria are the most
common signs of severity in young children, although this
pattern varies by age, with cerebral malaria becoming more
common in older children.17
What about malaria in pregnancy?
Treat pregnant women as having potentially complicated
malaria, although not all will need parenteral treatment. The
risks associated with severe disease are greater than in
non-pregnant women, and there are serious risks to the
pregnancy, including miscarriage, in otherwise non-severe
disease.18 The management of malaria in pregnancy has
particular challenges,19 because of the risks the disease poses to
the pregnancy and because the theoretical risks of teratogenicity
of antimalarial drugs need to be balanced with the substantial
risks of undertreating; specialist advice is strongly
recommended. Data from animals suggest that artemisinin drugs
are teratogenic in early pregnancy, but human data are
reassuring, with no current evidence of increased risk.20
Hypoglycaemia is a problem in pregnant women with malaria,21
and any pregnant woman with a reduced level of consciousness
should be given glucose while awaiting blood glucose
measurements.
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How is uncomplicated non-falciparum
malaria managed?
Several case reports indicate that vivax malaria, and possibly
ovale and malariae malaria, cause severe disease more often
than was once thought,22 and their label as “benign” malaria is
misleading. However, patients with non-falciparum malaria
need to be admitted only if they have indicators of severe disease
(table 1) or cannot take oral drugs. Provided the laboratory
making the diagnosis is experienced and unlikely to have
mistaken falciparum or rare mixed species infection (<1%),
chloroquine remains the drug of choice to treat vivax, ovale,
and malariae malaria. There is limited but growing chloroquine
resistance in vivax in eastern Asia and the Pacific.23 Evidence
from clinical trials and a systematic review shows that most
patients with vivax malaria, even those from South Asia or East
Asia, respond to chloroquine within three days (see table 2⇓ for
dosing).24 Good evidence from clinical trials shows that
artemisinin combination treatment (ACT) or quinine both work
against vivax malaria at the same doses as those used for
falciparum malaria (see below) if there is uncertainty about
species or in patients with mixed infections.25
The biggest difficulty in managing patients with vivax or ovale
malaria is that they can relapse several times after an initial
episode, often more than a year after initial infection.
Chloroquine and ACT treat the initial infection but do not kill
the hypnozoites in the liver, which cause recurrent malaria.
Primaquine is the only drug currently licensed to kill these
hypnozoites and prevent or reduce the risk of relapse.26 Apart
from the need for a two week course, primaquine has two
disadvantages. Firstly, resistance is gradually spreading,
particularly in Oceania and eastern Asia, so that higher doses
are now needed.27 In the United States and UK, the current
recommended dose for vivax malaria in adults is 30 mg a day
for 14 days (15 mg a day for ovale). In addition, case reports
and observational studies have found that treatment with
primaquine in patients with phenotypic glucose-6-phosphate
dehydrogenase (G6PD) deficiency can lead to haemolysis, which
can be life threatening. G6DP deficiency therefore needs to be
excluded before the drug is taken.28G6PD deficiency can affect
more than 10% of the population in malaria endemic countries,
although its prevalence is lower in people with malaria.29 30
Patients should not take primaquine until their G6PD status is
known, but treatment with chloroquine must not be delayed.
Unfortunately, the only new anti-hypnozoite drug likely to be
licensed in the next few years, tafenoquine, has similar risks
with G6PD deficiency.
How should uncomplicated falciparum
malaria be managed?
The severity of uncomplicated falciparum malaria is difficult
to assess at presentation owing to the complex life cycle of the
parasites, so all patients presenting with falciparum malaria in
non-endemic countries should be admitted. Patients can seem
well initially and then deteriorate despite treatment, and in
around 20% of patients the parasite count rises in the first 24
hours despite adequate treatment.7 Do not assume that patients
who once lived in endemic countries but now are settled in
non-endemic countries retain immunity. Clinical studies show
that although being born in endemic Africa reduces the risk of
dying from malaria, admission to intensive care and death can
still occur.6 31
Provided oral treatments can be tolerated, parenteral treatment
is not needed if there are no clinical or laboratory signs of
severity (table 1). Because of a lack of evidence, guidelines vary
about the threshold parasite count above which to give parenteral
treatment in patients without symptoms or signs of severity:
UK guidelines (designed for non-endemic countries) suggest
parasite counts over 2%, whereas WHO suggests over 5%.
Chloroquine resistance is near universal, so this drug should
not be used. A variety of drug combinations are effective against
uncomplicated falciparummalaria (table 2). Falciparummalaria
should always be treated with a combination of at least two
drugs. Commonly used options includeACTs, quinine combined
with another drug, and atovaquone-proguanil.Most non-endemic
countries have evidence based expert recommendations that are
periodically updated on the basis of trends in epidemiology of
imported malaria, emerging drug resistance, and local
availability of drugs.32 33
There is good evidence from large trials and systematic reviews
that ACT or quinine based combinations will be effective in
malaria from Africa, most of Asia, and Latin America; ACT
drugs are generally better tolerated and reduce parasite counts
more rapidly.34 Two ACTs, artemether-lumefantrine and
dihydroartemisinin-piperaquine, are currently licensed in Europe
and may become available in the US.
Is malaria resistance increasing?
P falciparum has developed resistance to several older
antimalarials, and resistance continues to evolve. Several clinical
studies show clear evidence of early emerging artemisinin
resistance in South East Asia (Cambodia, Thailand, and parts
of Burma), although ACTs still work clinically.35 Clinical trials
have also noted partial quinine resistance in the same area.
Several recent trials have found no evidence that quinine or
artesunate resistance is a serious clinical problem outside these
areas. Resistance to some older companion drugs (such as
sulfadoxine-pyrimethamine) is widespread, but well conducted
trials (in endemic countries) and observational data (in imported
cases) show that the combinations in table 2 are effective for
most (>95%) cases of importedmalaria. Atovaquone-proguanil
has been associated with occasional treatment failure in some
case reports, so many centres do not use it as first line
treatment36; it should not be used in people who have been taking
it prophylactically. Atovaquone-proguanil may be appropriate
second line treatment for the rare cases of treatment failure with
effective first line combinations, particularly those from South
East Asia. Falciparummalaria does not relapse and patients can
be reassured that they are unlikely to have recurrent malaria if
they complete a full course of treatment. Any further attacks
(generally within six weeks) usually represent treatment failure.
Warn travellers about the growing problem of poor quality and
counterfeit antimalarial drugs in many endemic countries.37
How should severe and potentially
complicated malaria be managed?
Severe malaria is a medical emergency, and the main priority
is for patients to receive adequate doses of effective drugs as
soon as possible. Quinine (quinidine in the US, which is broadly
equivalent) or artesunate are the two drugs used for parenteral
treatment of severe malaria. Clear evidence from large
randomised trials now shows that although quinine remains
effective, artesunate is associated with a survival advantage
(relative risk reduction of 22-34%) in adults and children in
Asia and Africa.38 39 Previously, the poor quality and limited
availability of parenteral artesunate has been a problem in many
non-endemic countries. However, although not licensed in
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Europe or the US, parenteral artesunate of reliable quality can
now be sourced (including through the Centers for Disease
Control and Prevention in the US). Patients should always be
started on parenteral quinine while trying to obtain artesunate
if it is not initially available to avoid delay in effective treatment.
In adults, artesunate confers the greatest survival benefit in those
with very high parasite counts (>10%).22 Parenteral quinine and
quinidine are associated with hypoglycaemia and arrhythmia
so should be used with caution in patients with cardiac problems.
Other than antimalarials, good management of patients with
severe malaria largely depends on supportive care, including
dialysis or haemofiltration in those with renal failure and
respiratory support for those with acute lung injury. Various
adjunctive treatments have been tried in cerebral
malaria—including steroids, mannitol, and anti-tumour necrosis
factor—none of which has shown a survival advantage.
For many years, there has been controversy over the use of
exchange transfusion or automated red blood cell exchange to
reduce parasite counts in patients with hyperparasitaemia
(generally >10%).40 The advent of treatment with artesunate,
when available, renders this debate irrelevant. Unlike quinine,
artesunate kills parasites of all stages and rapidly reduces
parasite counts. Exchange transfusion is now rarely indicated
and should be used only after discussion with a specialist centre.
The optimum management of fluids in adults and children has,
in the absence of good data, been highly controversial. A recent
trial in African children showed convincingly that aggressive
fluid management was associated with increased mortality.41
Good data on the optimal management of fluids in adults or
children in high resource settings are limited. In adults,
particularly those with renal failure, the risks of undertreating
acidosis and any pre-renal component if fluids are withheld
must be balanced against provoking pulmonary oedema if excess
fluids are used. Most doctors used to treating severe malaria are
wary about the overuse of fluids once pre-renal failure has been
ruled out by short, small fluid challenges; unlike in bacterial
sepsis, shock is rare in adults with malaria.
Clinical observational studies have shown a clear association
between severe malaria and Gram negative sepsis in children,
and reductions in the incidence of malaria in populations have
been associated with reductions in Gram negative bacteria.42 43
Broad spectrum antibiotics should therefore be considered in
all children with severe malaria. Data from adults are limited,
but the association seems to be less pronounced, so routine
antibiotics are not needed.44 Case reports suggest that broad
spectrum antibiotics should be given to the rare adult patients
who have shock with malaria.
Acute respiratory distress syndrome is the most feared late
complication of malaria in adults. In severe malaria, this can
occur several days after treatment has started, including when
parasites have cleared from the blood. As with other causes of
the syndrome, it is important to maintain oxygenation with
respiratory support in intensive care and treat the underlying
infection. No adjunctive treatments have been shown to improve
outcomes in patients with this complication. Respiratory distress
is also a poor prognostic sign in African children,11 but less so
in Asia (perhaps because of greater availability of blood
transfusions)45; it is almost always caused by acidosis rather
than lung injury.11
What is the prognosis after malaria?
The outlook for adults who survive an initial episode of malaria
is good, even for those with severe malaria. Serious neurological
sequelae occur in less than 5% of adults with severe malaria,
although few series have been large enough to provide confident
estimates. Many of the estimates in the literature are based on
expert opinion rather than data.46 47Renal failure and lung injury
almost invariably resolve if patients survive. Neurological
deficits in children who have had cerebral malaria are now
recognised to be more common, up to 30% in some series,48 but
these are often more subtle than for other serious neurological
infections, such as meningitis.49
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Tables
Table 1 | WHO criteria for severe malaria, modified for non-endemic high resource settings (any one indicates potentially severe disease)*
ChildrenAdultsSymptoms, signs, and laboratory indicators of severe disease
++++++Reduced level of consciousness
+++Seizures
++++Respiratory distress
++++Severe anaemia (haemoglobin <70 g/L)*
+++Hypoglycaemia†
++++Renal failure
++++Hyperparasitaemia (>10% red cells parasitised)
++Disseminated intravascular coagulation
++Shock
Warning signs of potentially complicated malaria (requires parenteral treatment):
++Jaundice
++++Parasite count >2%
*+=rare; ++=uncommon; +++=common (definition depends on age, state of immunity, and other factors).
†Common in pregnant women.
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Table 2| Common licensed drugs, drug combinations, and drug doses for malaria
NotesDose in adultsDrug
Uncomplicated vivax, ovale, and malariae malaria
620 mg base, then 310 mg base at 6, 24, and 48 hoursChloroquine
Test for G6PD deficiency before patients take it30 mg per day for 14 daysPrimaquine (after chloroquine)
Uncomplicated falciparum malaria
4 tablets (adult) initially, followed by 5 further doses of 4 tablets at 8,
24, 36, 48, and 60 hours
Artemether-lumefantrine
Follow with clindamycin for 7 days, doxycycline for 7 days,
or sulfadoxine-pyrimethamine once; ringing in ears a
common side effect
600 mg every 8 hours for 7 days or until parasites have clearedQuinine combinations
Avoid if patients were on atovaquone-proguanil prophylaxis4 tablets once a day for 3 daysAtovaquone-proguanil
Severe or potentially complicated malaria
By slow infusion over 4 hours; hypoglycaemia and
arrhythmias are side effects
20 mg/kg quinine intravenously, followed by 10 mg/kg 8-12 hourly
until parasites have cleared
Quinine
As a bolus over 5 minutes2.4 mg/kg intravenously, followed by 2.4 mg/kg at 12 hours, then 2.4
mg/kg daily until parasites have cleared
Artesunate
G6PD=glucose-6-phosphate dehydrogenase.
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